| Filed On | Filing |
|---|---|
| 16 Aug 2023 |
8-K/A: Financial Statements and Exhibits
On June 30, 2023, Amphastar Pharmaceuticals, Inc., or the Company, completed its acquisition of BAQSIMI® glucagon nasal powder, or BAQSIMI®, or the Acquisition, pursuant to an asset purchase agreement, or the Purchase Agreement, with Eli... |
| 10 Aug 2020 | 8-K/A: Submission of Matters to a Vote of Security Holders |
| 14 Apr 2020 | 8-K/A: Departure/Election of Directors or Officers; Compensation |
Loading...
